Brief: Twist Bioscience Enters Into Antibody Discovery And Licensing Option Agreement With Bayer Of Up To $188 Mln

Twist Bioscience

05/10/2023 13:15

Oct 5 (Reuters) - Twist Bioscience Corp  TWST.O :
    * TWIST BIOSCIENCE ENTERS INTO ANTIBODY DISCOVERY AND
LICENSING
OPTION AGREEMENT WITH BAYER OF UP TO $188 MILLION
    * TWIST BIOSCIENCE CORP - UNIT TO CONDUCT ANTIBODY DISCOVERY
CAMPAIGNS AGAINST TARGETS TO BE DETERMINED BY BAYER.
    * TWIST BIOSCIENCE CORP - BAYER WILL HAVE THE OPTION TO
LICENSE
ANTIBODIES DISCOVERED UNDER THE COLLABORATION.
    * TWIST BIOSCIENCE CORP - TO RECEIVE PAYMENTS CONNECTED WITH
INITIATION OF RESEARCH
    * TWIST BIOSCIENCE CORP - TO BE ELIGIBLE TO RECEIVE FEES
ASSOCIATED WITH RESEARCH MILESTONES AND THE EXERCISE OF
LICENSING OPTIONS.
    * TWIST BIOSCIENCE CORP - BAYER RECEIVES EXCLUSIVE RIGHTS TO
LICENSE THE ANTIBODIES FOR COMMERCIALIZATION IN ALL GLOBAL
TERRITORIES

Source text for Eikon:  ID:nBw9BSPmka 
Further company coverage:  TWST.O 

 ((Reuters.Briefs@thomsonreuters.com;))